Case Report
High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis
Table 1
Details of chemotherapy and CBT.
| | Induction chemotherapy | | | Cyclophosphamide | 1,200 mg/m2/day on days 1 and 2, except for day 2 in cycle 1 | | Vincristine | 1.5 mg/m2 on day 1 | | Pirarubicin | 40 mg/m2 on day 3 | | Cisplatin | 20 mg/m2/day continuously from days 1 to 5 | | HDC with auto-PBSCT | | | Melphalan | 100 mg/m2/day on days -9 and -8 | | Etoposide | 200 mg/m2/day on days -7 to -4 | | Carboplatin | 400 mg/m2/day continuously on days -7 to -4 | | Cord blood transplantation | | | Conditioning regimen | | | Fludarabine | 25 mg/m2/day on days -7 to -3 | | Melphalan | 70 mg/m2/day on days -4 and -3 | | TBI | 2 Gy on day -2 | | GVHD prophylaxis | Tacrolimus and short-term methotrexate |
| | HLA typing | A | B | C | DRB1 |
| | Recipient | 24:02/— | 51:01/52:01 | 12:02/14:02 | 04:05/15:02 | | Donor | 24:02/— | 51:01/52:01 | 12:02/15:02 | 15:02/— |
|
|
CBT: cord blood stem cell transplantation; HDC: high-dose chemotherapy; auto-PBSCT: autologous peripheral blood stem cell transplantation; TBI: total body irradiation; GVHD: graft-versus-host disease; HLA: human leukocyte antigen.
|
